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Background: Chronic Pseudomonas aeruginosa (PA) infection causes increased morbidity and mortality in cystic fibrosis (CF). This study aimed
to answer the following questions: Does the prevalence of chronic infection with PA differ between the CF centres in Scandinavia? Which
differences exist concerning segregation and treatment of PA?
Methods: 989 patients (86%) from all eight CF-centres in Scandinavia were included. Demographic and clinical data, including PA colonisation
status based on cultures and serology, were recorded at inclusion. The patients were followed prospectively for 1 year, recording number of days
with anti-PA antibiotic treatment.
Results: In all pancreatic insufficient (PI) patients (n=890) the prevalence of chronic PA infection at each centre ranged from 25.8% to 48.9%, but
were not significantly different. In PI patients b19 years the prevalence was 14.5% in Copenhagen compared to 30.9% in the Swedish centres
pooled (p=0.001). In intermittently colonised PI patients b19 years the median number of days per year on anti-PA antibiotics was almost 6 times
higher in Copenhagen (mean 86 (110), median 61 days) compared to the Swedish centres pooled (mean 27 (52), median 11 days) (p=0.037). The
pulmonary function was similar.Abbreviations: SCFSC, Scandinavian CF Study Consortium; PA, Pseudomonas aeruginosa; CF, cystic fibrosis; PI, pancreatic insufficient; CIE, crossed
immunoelectrophoresis; FEV1, forced expiratory volume in one second; CFTR, Cystic fibrosis transmembrane conductance regulator.
☆ Data from the manuscript were presented at the 28th European Cystic Fibrosis Conference, Crete, Greece, 22–25 of June 2005 and at the 19th Annual North
American Cystic Fibrosis Conference, Baltimore, USA, 20–23 of October 2005.
⁎ Corresponding author. National Center for Cystic Fibrosis, Ullevaal University Hospital, Kirkeveien 166, N-0407 Oslo, Norway. Tel.: +47 23 01 55 90; fax: +47 23
01 55 91.
E-mail address: pekn@uus.no (P.K. Knudsen).
1 Members of the Scandinavian CF Study Consortium (SCFSC): Pål Leyell Finstad, National Center for Cystic Fibrosis, Ullevaal University Hospital, Oslo,
Norway; Gjermund Fluge, Department of Pediatrics, Haukeland University Hospital, Bergen, Norway; Anne Geborek, Stockholm Cystic Fibrosis Centre, Karolinska
University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; Marita Gilljam, Dept Pulmonary Medicine and Allergology, Gothenburg University,
Sahlgrenska University Hospital, Gothenburg, Sweden; Nils Olav Hermansen, Department of Microbiology, Ullevaal University Hospital, Oslo, Norway; Lena Hjelte,
Stockholm Cystic Fibrosis Centre, Karolinska University Hospital Huddinge, Karolinska Institutet, Stockholm, Sweden; Helle Krogh Johansen, Department of
Clinical Microbiology, Copenhagen University Hospital, Copenhagen, Denmark; Mary Kämpe, Uppsala CF Center, Uppsala University Hospital, Uppsala, Sweden;
Lena Mared, Heart and Lung Center, Lund University Hospital, Lund, Sweden; Helge Michalsen, Department of Pediatrics, Sørlandet Hospital, Arendal, Norway;
Peter Oluf Schiøtz, Department of Pediatrics, Aarhus University Hospital Skejby, Aarhus, Denmark; Bjørn Skrede, National Center for Cystic Fibrosis, Ullevaal
University Hospital, Oslo, Norway; Olav-Trond Storrøsten, National Center for Cystic Fibrosis, Ullevaal University Hospital, Oslo, Norway.
1569-1993/$ - see front matter © 2008 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.
doi:10.1016/j.jcf.2008.11.001
136 P.K. Knudsen et al. / Journal of Cystic Fibrosis 8 (2009) 135–142Conclusions: It is possible to maintain a very low prevalence of chronic PA infection in CF patients b19 years. We speculate that this was most
likely due to a very intensive treatment of intermittently colonised patients with inhaled anti-PA antibiotics over prolonged periods of time in some
centres. Since lung function was similar in centres with less intensive use of inhaled antibiotics, studies comparing different treatment modalities
and other parts of CF care are needed to define the best clinical practice, including how to use antibiotics in the most rational way.
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The most common chronic bacterial pathogen in the cystic
fibrosis (CF) lung is Pseudomonas aeruginosa (PA) [1,2].
Chronic infection with PA is associated with a decline in lung
function [3,4] and increased morbidity and mortality [5,6].
Several studies have shown that early and aggressive antibiotic
treatment of PA can postpone and may prevent chronic infection
[7–10]. Different antibiotic treatment policies are used in dif-
ferent CF centres, but randomised controlled studies comparing
different antibiotic treatment regimens have not been published
[11].
Pulmonary infection with PA causes an immune response
producing detectable antibodies against specific bacterial anti-
gens. The response is even more pronounced in chronic
infection with mucoid PA strains [3,12]. In Danish studies the
level of crossed immunoelectrophoresis (CIE) precipitating
antibodies (precipitins) against PA showed high sensitivity and
specificity for detecting patients with chronic infection [13,14].
Evidence for cross infection with PA between CF patients
with epidemic strains [15–17] and after prolonged close social
contact (summer/winter camps, physical training courses etc)
have been published [18,19]. Other publications report low
grade of cross infection [20,21]. Consequently, the question
whether patients harbouring PA should be segregated from
patients not having the bacteria, is debated [22].
Studies focusing on the impact of differences in treatment
policies between CF centres in Scandinavia on the prevalence of
chronic PA infection have not been performed. This study
aimed to answer the following questions: Does the prevalence
of chronic infection with PA differ between the CF centres in
Scandinavia? Which differences exist between centres concern-
ing antibiotic treatment strategies, but also segregation- and
bacteriological surveillance strategies for PA? Does the
prevalence of other chronic Gram-negative infections differ
between the centres?
2. Methods
2.1. Patients
The study was initiated by the Scandinavian CF Study
Consortium (SCFSC), and all eight CF-centres in Scandinavia
participated in the study: Denmark: Aarhus, Copenhagen;
Norway: Bergen, Oslo; Sweden: Gothenburg, Lund, Stoc-
kholm and Uppsala. Patients were included consecutively from
August 2001 to June 2003, when in clinical stable condition.Exclusion criterion was lung transplant. Patients using pan-
creatic enzymes were classified as pancreatic insufficient (PI).
2.2. Collection of data
Demographic and clinical data, including PA colonisation
status, were recorded at inclusion and the patients were fol-
lowed prospectively for 1 year. During the study period, days
when antibiotics directed against PA were given, and mode of
administration (intravenous (iv), inhaled, oral), were recorded
and expressed as number of days per calendar year. When
treatment modes were combined, the more “intensive” mode of
administration was recorded (ivNinhalationNoral, e.g. in case of
combination of iv and inhaled and/or oral antibiotics, only iv
administration was recorded). As no centre used oral quinolones
as monotherapy against PA, consequently only days with iv or
inhaled anti-pseudomonas treatment were recorded. Patients
with an inclusion period of less than 275 days, or more than
500 days from the date of inclusion to the date of the end of the
study, were excluded from calculations of number of days on
antibiotic treatment. Serum samples were obtained a inclusion
and at the end of the study for analyses of CIE precipitating
antibodies (precipitins) to PA [13]. The precipitin analyses were
performed in Copenhagen for all patients.
Lung function test was performed at inclusion (patients older
than 6 years) by dynamic spirometry at each centre, according to
the local routine. From measured forced expiratory volume in
1 second (FEV1) in litres, percentage of predicted values were
calculated using Solymar [23] and Quanjer [24] reference equa-
tions for patients younger and older than/or 19 years, respectively.
Data on policies for surveillance, segregation and treatment
of PA were obtained from questionnaires sent to each of the
eight participating centres.
2.3. Comparison of the CF centres
Data from all the eight participating centres are presented in
tables. Presenting comparisons of all pairs of centres is
didactically difficult. It was therefore decided to pool the four
Swedish centres in Gothenburg, Lund, Stockholm and Uppsala
since theywere found to be very similar concerning strategies for
antibiotic treatment and segregation policies. The centre in
Copenhagen was known to have a different approach to anti-
biotic treatment and segregation compared to Swedish centres
and also differing from the other Danish centre located in
Aarhus. It was therefore decided to make comparisons between
Copenhagen separately and the four Swedish centres pooled.
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2.4.1. Pseudomonas aeruginosa
Chronic infection: Repeated positive bacterial cultures (≥3)
during the last six months and/or 2 or more CIE precipitins
against PA. Intermittent colonisation: PA cultured at least once
during life, but less than three positive cultures during the last
six months and precipitins less than 2. Not colonised: PA never
cultured and 0–1 precipitins (=normal values).
2.4.2. Other Gram-negative bacteria
Classification of chronic infection with other Gram-
negative bacteria was based on each centres own definition,
usually three or more positive cultures during a six month
period.
2.5. Statistical analysis
Fischer's exact two-sided test was used to compare cate-
gorical data (prevalence and incidence of chronic infections)
in two groups. Logistic regression with chronic infection as
dependent variable and age and centre as covariates was used
when comparing centres with different mean age. IndependentTable 1
Antibiotic treatment policies against Pseudomonas aeruginosa at the eight Scandina
First PA infection Intermittent PA colonisation
Aarhus Oral ciprofloxacin+
inhaled antibiotics⁎,
3 weeks
Oral ciprofloxacin+ inhaled antibiotics⁎
3 months if recurrent infection
Copenhagen Oral ciprofloxacin+
inhaled colistin,
3 months
Oral ciprofloxacin+ inhaled colistin,
3 months. Iv if recurrent isolate during
treatment, or mucoid phenotype, or
increasing antibodies
Bergen Oral ciprofloxacin+
inhaled antibiotics⁎,
4 weeks. Small children:
14 days iv
Oral ciprofloxacin+ inhaled antibiotics⁎
3 months if recurrent infection
Oslo Oral ciprofloxacin+
inhaled colistin,
3 weeks. Small children:
14 days iv
Oral ciprofloxacin+ inhaled antibiotics⁎
Duration varies. Sometimes 14 days iv
Gothenburg 10 days iv. Followed
by inhaled antibiotics⁎,
4 weeks since 2000
10 days iv. Followed by inhaled
antibiotics⁎, 4 weeks since 2000
Lund 10 days iv, followed by oral
ciprofloxacin and/or inhaled
antibiotics⁎. Information of
duration not given
10 days iv, followed by oral ciprofloxac
and/or inhaled antibiotics⁎. Information
of duration not given
Stockholm 10 days iv (Repeated within
a month if no eradication)
10 days iv, followed by inhaled
antibiotics⁎ in selected cases
Uppsala 10–14 days iv followed
by inhaled tobramycin and
oral ciprofloxacin and
azithromycin, 3 months
10–14 days iv followed by inhaled
tobramycin and oral ciprofloxacin and
azithromycin, 3 months
⁎Colistin or tobramycin.
PA, Pseudomonas aeruginosa; iv, intravenous.t-test was used to compare normally distributed continuous
data (age, FEV1) in two groups. Linear regression with FEV1
as dependent variable and age and centre as independent
variables was used when comparing centres with different
mean age. Mann-Whitney U-test was used to compare con-
tinuous variables with skewed distribution (number of days
per year with antibiotic treatment). The significance level was
set to 5%. The statistical analyses were performed by SPSS
version 14.0.
2.6. Ethics
The Regional Research Ethics Committees in each country
approved the study and informed written consent was obtained
from all patients.
3. Results
3.1. Policies for patient segregation, bacteriological
surveillance and treatment of PA
The antibiotic treatment policies at each centre are presented
in Table 1.vian CF centres
Chronic PA infection Azithromycin
treatment
Cultures per year
from non-sputum
producing patients
. 14 days iv every 3. month /
on demand. Aprox. 50% of
patients: Inhaled antibiotics⁎
Not used at the
time of the study
10–11 (laryngeal
aspiration)
14 days iv every 3. month.
Continuous inhaled
antibiotics⁎ between iv
Patients with chronic
PA infection
12 (laryngeal
aspiration)
. 12–14 days iv every 3. month.
Selected patients: Inhaled
antibiotics⁎ between iv
Selected patients
with chronic PA
infection
4–6 (laryngeal
aspiration)
. 14 days iv every 3. month.
Most patients: Inhaled
antibiotics⁎ between iv
No strict policy 9 (laryngeal
aspiration)
10 days iv on demand Patients with chronic
PA infection
4 (nasopharyngeal
swab)
in 10 days iv on demand.
Selected patients: Inhaled
antibiotics⁎
Patients with chronic
infections or much
sputum
0
10 days iv on demand.
Selected patients: Inhaled
antibiotics⁎
Selected patients with
chronic PA infection
5–6
(nasopharyngeal
swab)
10–14 days iv on demand.
Selected patients: Inhaled
antibiotics⁎ and/or oral
ciprofloxacin
Patients with chronic
PA infection
4 (nasopharyngeal
swab)
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every 4th to 6thweek. Patients inNorway andSweden living long
distances from their CF centre, were seen by their local doctor
between their yearly (or more frequent) visits at the centre (e.g.
shared care with the local hospitals). Bacteriological cultures
were obtained from sputum-producing patients at every visit and
if the patients noticed symptoms of exacerbation between regular
visits. The major differences between centres/countries were:
1. Patient segregation at the outpatient clinic according to PA
colonisation status was not practiced in any Swedish centre,
in contrast to Danish and Norwegian centres.
2. Bacteriological cultures from non-sputum-producing
patients were obtained less often in Sweden compared toTable 2
Demographic and clinical data on patients from the eight Scandinavian CF centres
A, Aarhus; C, Copenhagen; B, Bergen; O, Oslo; G, Gothenburg; L, Lund; S, Stock
F, female; PS, pancreatic sufficient; PI, pancreatic insufficient; y, years; PA, Pseud
Stenotrophomonas maltophilia; AX, Achromobacter xylosoxidans; FEV1, forced ex
⁎C vs G+L+S+U.
# Patients homozygous or compound heterozygous for class I or class II CFTR mu
† One or both mutations unknown.
¶ Logistic regression with chronic PA infection as dependent variable and group (C
§ Linear regression with FEV1 as dependent variable and group (C and G+L+S+Denmark and Norway using laryngeal aspiration at every
visit.
3. The main eradication policy of first and intermittent PA
infection was 10 days of iv antibiotics in Sweden, but inhaled
antibiotics (colistin or tobramycin) in combination with oral
ciprofloxacin for several weeks/months in Denmark and
Norway.
4. Patients with chronic PA infection were given iv antibiotics
on demand in Sweden and in Aarhus, but regularly every 3rd
month in Copenhagen and in Norway.
5. Suppression therapy (inhaled colistin or tobramycin) be-
tween iv courses was given regularly to patients with chronic
PA infection in Copenhagen, to some extent in Aarhus,
Bergen and Oslo, but seldom in Swedish centres.and from the Swedish centres pooled
holm; U, Uppsala.
omonas aeruginosa; BC, species of the Burkholderia cepacia complex; SM,
piratory volume in 1 s.
tations.
and G+L+S+U) and age as covariates.
U) and age as independent variables.
Fig. 1. Prevalence of chronic infection with Pseudomonas aeruginosa in 890
pancreatic insufficient CF patients in Denmark, Norway and Sweden.
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989 (48% females) cystic fibrosis patients were included in
the study, accounting for about 86% of the Scandinavian CF
population. Demographic and clinical data from each centre are
shown in Table 2. The frequency of PI patients was higher in
Denmark, due to differences between the countries in distribu-
tion of CFTR mutations (Table 2). Due to this huge difference
in prevalence of pancreatic insufficiency, a known risk factor
for pseudomonas colonisation and deterioration of lung func-
tion, only PI patients (n=890 (47% females)) were included
in the further analyses, diminishing the differences between
the countries related to differences in distribution of CFTR
mutations.
3.3. Prevalence of chronic PA infection
The prevalence of chronic PA infection in each country is
shown in Fig. 1, and for each centre in Table 2.
When comparing the prevalence in all pairs of centres, after
correcting for differences in age, only Oslo and Stockholm were
found to be significantly different (p=0.041). The prevalence
did not differ between Copenhagen and the pooled Swedish
centres (Table 2).Table 3
Mean (SD), median days per year on antibiotics against PA in patients with pancrea
⁎C vs G+L+S+U.
#No other chronic Gram-negative infection.
PA, Pseudomonas aeruginosa; A, Aarhus; C, Copenhagen; B, Bergen; O, Oslo; G, GIn patientsb19years theprevalenceof chronicPA infectionwas
similar in the four centres in Denmark and Norway (p-values not
shown), but was significantly lower in Copenhagen compared to
each of the three larger Swedish centres: Gothenburg (p=0.037),
Lund (p=0.019), Stockholm (pb0.001), and compared to the four
Swedish centres pooled (p=0.001) (Table 2). However, the pre-
valence was similar in Copenhagen and at the smallest Swedish
centre in Uppsala (p=1.0). The prevalence was significantly
higher in Stockholm compared to the other three centres in
Denmark andNorway:Aarhus (p=0.004), Bergen (p=0.045) and
Oslo (p=0.013), and when compared to Uppsala (p=0.045).
3.4. Incidence of chronic PA infection
500 of the PI patients were not chronically infected with PA
at inclusion. PA colonisation status at the end of the study was
available from 456 of these patients with mean age 12.7 (9.4)
years. The mean number of days from the start to the end of the
study was 374 (35). During the observation period 33 patients
(7.2%) became chronically infected with PA. The incidence was
6.3% in Denmark, 5.2% in Norway and 9.4% in Sweden. The
incidence in Sweden was more than twice the incidence in
Copenhagen: 5/120 (4.2%), but this difference did not reach
statistical significance (p=0.11).
3.5. Prevalence of other infections
The prevalence of other chronic infections at each centre are
shown in Table 2. Chronic infection with Achromobacter
xylosoxidans was only found in Danish patients, and the
prevalence of both A. xylosoxidans and species of the Bur-
kholderia cepacia complex was significantly higher in
Copenhagen compared to the Swedish centres pooled.
3.6. Use of antibiotics directed against PA
3.6.1. Patients chronically infected with PA
The use of antibiotics differed between centres, also within
the same country, shown in Table 3. When comparing Co-
penhagen and the pooled Swedish centres, the number of daystic insufficiency at each centre and the Swedish centres pooled
othenburg; L, Lund; S, Stockholm; U, Uppsala; Iv, intravenous.
Table 4
Prevalence of pancreatic insufficient patients younger than 19 years getting
other medication at each centre
Denmark Norway Sweden
Centres A C B O G L S U
Number of patients 80 124 23 67 53 49 95 23
Dornase alpha (%) 70 99 35 45 30 59 26 0
Inhaled N-acetylcysteine (%) 0 0 96 91 66 10 90 39
Oral N-acetylcysteine (%) 1 14 91 49 9 20 77 39
Oral bromhexin (%) 0 0 0 2 98 25 98 100
Inhaled steroids (%) 15 27 13 9 13 18 13 44
Oral steroids (%) 3 10 0 2 0 0 0 4
Continuous macrolides (%) 0 23 9 5 40 39 14 17
A, Aarhus; C, Copenhagen; B, Bergen; O, Oslo; G, Gothenburg; L, Lund;
S, Stockholm; U, Uppsala.
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reflecting the difference in treatment policy. Also the number of
days per year with intravenous antibiotics was significantly
higher in Copenhagen, using regular intravenous courses,
compared to the Swedish centres, using intravenous antibiotics
on demand.
3.6.2. Patients b19 years old intermittently colonised with PA
The number of days per year with antibiotics to patients
b19 years intermittently colonised with PA and not having
chronic infection with any other Gram-negative bacteria, is
shown in Table 3. The number of days per year with inhaled
antibiotics was significantly higher in Copenhagen compared to
the pooled Swedish centres. In contrast, the number of days per
year with intravenous antibiotics was higher in the Swedish
centres. In total, the use of antibiotics calculated as the number
of days per year with inhaled and/or intravenous antibiotics, was
significantly higher in Copenhagen.
3.7. Lung function
Lung function for each centre and for the Swedish centres
pooled are shown in Table 2. There were no significant dif-
ferences in FEV1 between Copenhagen and the Swedish centres
pooled, neither for all PI patients nor for subgroups (PI patients
b19 years, PI patients with chronic PA infection).
3.8. Other treatment
Data on other medical treatment are shown in Table 4. The
treatment differed between centres. One major difference was
that Dornase alpha was the most prevalent mucolytic agent used
in Denmark in contrast to most Norwegian and Swedish centres
using inhaled N-acetylcysteine. Oral bromhexin was used only
in Sweden.
4. Discussion
This study explored the policies for treatment and prevention
of PA and the prevalence of chronic PA infection in eight CF-
centres in three geographically and socially similar countries.The policies for segregation of patients infected with PA
differed with strict segregation at the centres in Denmark and
Norway, but not in Sweden. Antibiotic treatment of PA in-
fections was significantly different with antibiotics given more
days per year to patients mainly in Copenhagen but also in
Aarhus and in the Norwegian centres compared to the Swedish
centres. The prevalence of chronic PA infection was similar in
all centres when all age groups were included, but significantly
higher in the pooled Swedish centres compared to Copenhagen
in patients b19 years. This was further supported by a trend
towards a higher incidence of chronic PA infection in Sweden
during the study period.
One major obstacle of comparisons between centres is
different definitions regarding criteria for classification of PA
infection status. Definitions only relying on cultures depend on
number of cultures obtained over a time period, how the
cultures are obtained and facilities at the local microbiology
laboratory. This was overcome in this multi-centre study by
defining chronic PA infection with a combination of repeated
positive cultures and/or ≥2 CIE precipitins against PA detected
[13]. The precipitin analyses were centralised to Copenhagen.
The prevalence of chronic PA infection in each centre is thus
based on the same diagnostic test and is directly comparable.
Only one of all chronically infected patients had less than two
precipitins (but three or more positive cultures during a six
month period).
The prevalence of chronic PA infection was low in all centres
compared to other published data [2,25], and the prevalence was
probably not underestimated. Instead the prevalence was slightly
overestimated since there is a known serological cross-reaction
with other Gram-negative bacteria like A. xylosoxidans, species
of the B. cepacia complex and Stenotrophomonas maltophilia
[26,27]. Some patients were therefore classified as chronically
infected with PA but actually infected with another Gram-
negative bacteria. These patients were few, and it was decided by
the SCFSC that it was important to use a definition of chronic PA
infection that was robust and with no bias depending on clinical
practice.
There are various possible explanations to the difference in
prevalence of chronic PA infection in the younger cohort. First,
the eradication policy may be less effective in Sweden. Copen-
hagen introduced in the late 1980s inhalation of colistin and oral
ciprofloxacin as standard treatment once PA was detected,
increasing the dosage and length of treatment if recurrent in-
fections occurred. The Swedish centres have from the same time
adopted a policy with intravenous treatment for 10 days at first
infection and repeating this at recurrent infections. Only during
the last few years inhaled antibiotics have been added to the
eradication regimen in some centres in Sweden. Both the longer
duration and the mode of antibiotic therapy in Copenhagen may
be of importance for more successful eradication. Combining
inhaled and systemic treatment results in high concentrations of
antibiotics to both the central bronchi and sputum and to the
peripheral bronchioles and alveoli.
On the other hand, the longer periods with inhaled antibiotics
used by some of the intermittently colonised Copenhagen
patients raise the possibility of keeping patients in the group
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precipitins or recurrent positive cultures although the patient
may be culture-positive once the treatment stops. This possi-
bility is supported by the fact that some intermittently colonised
patients used anti-pseudomonas antibiotics for more days per
year in Copenhagen than chronically infected patients in
Sweden.
Thirdly, the infection might be detected earlier in Denmark
and Norway obtaining cultures from non-sputum producing
patients more frequently than in Sweden. Longer time from the
acquisition of the bacteria to the start of eradication treatment
may increase the risk of eradication failure.
A fourth explanation of higher prevalence might be a higher
incidence of cross infections in Swedish CF centres that do not
practice segregation at the outpatient clinic or at social events
like meetings and summer camps. This seems less likely since
pulse field gel electrophoresis analyses do not indicate spread of
epidemic strains within these centres until 2004 [28]. After this
study was ended, cross-infection between Swedish CF patients
during a winter camp has though been reported [29].
A higher prevalence of other Gram-negative chronic in-
fections was found in Copenhagen (A. xylosoxidans, species of
the B. cepacia complex) and Oslo (S. maltophilia). Reasons for
this can only be speculated on, but prolonged use of broad-
spectrum antibiotics might increase the risk of acquisition of
resistant pathogens. A multi-centre comparison suggested a
higher prevalence of resistant Gram-negative bacteria in centres
with more frequent antibiotic treatment [30].
Infection with PA has been linked to a decline in lung
function [3,4]. In this study we found at least as good lung
function in Swedish patients despite a higher prevalence of
chronic PA infection (patients b19 years old). One weakness of
the study is that FEV1 was only measured at inclusion making it
impossible to evaluate the annual decline in pulmonary function
in the different centres. Similar lung function in chronically
infected patients in Copenhagen and the Swedish centres
despite a more than 5-fold higher use of antibiotics against PA in
Copenhagen, makes it important to define other factors that can
affect the progress of CF lung disease. A higher prevalence in
Copenhagen of patients chronically infected with A. xylosox-
idans and species of the B. cepacia complex, known to cause a
fast decline in lung function in infected CF patients, may be one
such factor [31,32].
Some studies have shown a short term beneficial effect of
beta-2 agonists on lung function in CF patients, and a long-term
effect in CF patients with bronchial hyperreactivity [33]. Data
on use of beta-2 agonists were not collected in this study, but the
Swedish centres report that practically all their patients are
given nebulised beta-2 agonists once or twice daily, in contrast
to Danish and Norwegian centres where the treatment policy
varies. This may be a factor of importance for the FEV1
reported, since the spirometry procedures were not standardised
in relation to inhalation of beta-2 agonists.
We also speculate that frequent use of N-acetylcysteine in
Sweden may have a positive impact on the patients' pulmonary
function, although N-acetylcysteine was also prescribed to
Norwegian patients having lower lung function parameters.Clinical evidences of beneficial effects of N-acetylcysteine in
CF are scarce [34], however results from some published
studies suggest a possible positive effect of oral N-acetylcys-
teine on airway inflammation [35] and on lung function in CF
patients [36].
Other factors, such as nutrition, physiotherapy and exercise,
may also have an impact on pulmonary function. There are
differences in how physiotherapy and physical exercise are
performed at the different centres, but this question was not part
of the study.
The differences in practical CF care and medication, in-
cluding use of antibiotics, were huge (Table 3 and 4). These
differences were not dependent on economical factors in the
three countries but on individual decisions at each centre of how
to treat. The divergences of treatment strategies between centres
and countries were surprising to the members of the consortium,
indicating lack of consensus and clear treatment recommenda-
tions. This implies that benchmarking between centres should
include not only simple measures like lung function and weight
but also treatment policies.
In conclusion, the prevalence of chronic PA infection was
low in all Scandinavian CF centres compared to other published
data. The prevalence among patients b19 years was signifi-
cantly lower in Copenhagen compared to Sweden. Copenhagen
and the Swedish centres differed both concerning mode and
duration of antibiotic treatment against PA and the annual
number of cultures obtained. These factors may be of im-
portance for the observed difference in prevalence of chronic PA
infection. Despite the differences in PA prevalence and use of
antibiotics, the patients attending these centres had similar lung
function. More studies comparing different treatment modalities
and other parts of CF care are needed to define the best clinical
practice, including how to use antibiotics in the most rational
way.
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